Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
96
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Neural Regulation01:37

Neural Regulation

39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.

medRxiv : the preprint server for health sciences·2026
Same author

Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.

medRxiv : the preprint server for health sciences·2026
Same author

Development and validation of MethylCog, a blood DNA methylation proxy for cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Cognitive Fluctuations, Neuropsychiatric Burden, and Quality of Life in Moderate-Advanced Dementia With Lewy Bodies: The Role of Dysautonomia.

Neurology·2026
Same author

Associations between self-reported change in lifestyle behaviors and brain health: Findings from the Healthy Brain Initiative.

Journal of Alzheimer's disease : JAD·2026
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.5K

Lewy Body Dementia.

James E Galvin

    Continuum (Minneapolis, Minn.)
    |December 2, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Lewy body dementia (LBD), encompassing Parkinson disease dementia and dementia with Lewy bodies, is a common neurodegenerative condition. Early recognition through understanding key features and biomarkers is crucial for timely diagnosis and treatment.

    More Related Videos

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    17.3K
    A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
    07:08

    A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

    Published on: October 20, 2016

    7.8K

    Related Experiment Videos

    Last Updated: Jun 6, 2025

    Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
    10:03

    Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

    Published on: August 16, 2020

    10.5K
    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    17.3K
    A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
    07:08

    A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

    Published on: October 20, 2016

    7.8K

    Area of Science:

    • Neuroscience
    • Neurology
    • Geriatrics

    Background:

    • Lewy body dementia (LBD) is an umbrella term for Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB).
    • It is the second most common cause of neurodegenerative dementia, frequently underrecognized in clinical practice.
    • Delayed diagnosis and treatment of LBD increase patient and caregiver burden.

    Purpose of the Study:

    • To review the epidemiologic, clinical, cognitive, behavioral, and biomarker features of LBD.
    • To discuss current treatment options for LBD.
    • To highlight the importance of early detection and the role of biomarkers in improving LBD recognition.

    Main Methods:

    • Review of current literature on Lewy body dementia.
    • Analysis of diagnostic criteria and prodromal stages of PDD and DLB.
    • Examination of indicative and developing biomarkers for LBD diagnosis.

    Main Results:

    • Indicative biomarkers include SPECT imaging of dopamine and noradrenergic systems, and polysomnography.
    • α-Synuclein biomarkers in various bodily fluids and imaging are under development.
    • Published diagnostic criteria and contextualized prodromal stages for PDD and DLB exist.

    Conclusions:

    • Understanding LBD's key features and utilizing biomarkers can improve diagnostic accuracy and timeliness.
    • Earlier detection of LBD facilitates new therapeutic development and clinical trial enrollment.
    • An integrated staging system based on protein aggregation may advance LBD research.